Experimental Validation of MHC Class I and II Peptide-Based Potential Vaccine Candidates for Human Papilloma Virus Using Sprague-Dawly Models

Ismail, Mehreen1; Bai, Baogang2,3,4; Guo, Jinlei5; Bai, Yuhui6; Sajid, Zureesha1; Muhammad, Syed Aun1; Shaikh, Rehan Sadiq1,7

2023-02-01

10.3390/molecules28041687

MOLECULES   Impact Factor & Quartile

1420-3049

Human papilloma virus (HPV) causes cervical and many other cancers. Recent trend in vaccine design is shifted toward epitope-based developments that are more specific, safe, and easy to produce. In this study, we predicted eight immunogenic peptides of CD4+ and CD8+ T-lymphocytes (MHC class I and II as M1 and M2) including early proteins (E2 and E6), major (L1) and minor capsid protein (L2). Male and female Sprague Dawly rats in groups were immunized with each synthetic peptide. L1M1, L1M2, L2M1, and L2M2 induced significant immunogenic response compared to E2M1, E2M2, E6M1 and E6M2. We observed optimal titer of IgG antibodies (>1.25 g/L), interferon-gamma (>64 ng/L), and granzyme-B (>40 pg/mL) compared to control at second booster dose (240 mu g/500 mu L). The induction of peptide-specific IgG antibodies in immunized rats indicates the T-cell dependent B-lymphocyte activation. A substantial CD4+ and CD8+ cell count was observed at 240 mu g/500 mu L. In male and female rats, CD8+ cell count for L1 and L2 peptide is 3000 and 3118, and CD4+ is 3369 and 3484 respectively compared to control. In conclusion, we demonstrated that L1M1, L1M2, L2M1, L2M2 are likely to contain potential epitopes for induction of immune responses supporting the feasibility of peptide-based vaccine development for HPV.

HPV epitope prediction peptides vaccine animal studies immunoassays

SCI

English

Others

Biochemistry & Molecular Biology ; Chemistry

Biochemistry & Molecular Biology ; Chemistry, Multidisciplinary

WOS:000940055600001

MDPI

CHEMISTRY

Web of Science

1.Bahauddin Zakariya Univ, Inst Mol Biol & Biotechnol, Multan 60800, Pakistan
2.Wenzhou Business Coll, Sch Informat & Technol, Wenzhou 325015, Peoples R China
3.Engn Res Ctr Intelligent Med, Wenzhou 325000, Peoples R China
4.Wenzhou Med Univ, Affiliated Hosp 1, Sch Med 1, Sch Informat & Engn, Wenzhou 325015, Peoples R China
5.Xinxiang Med Univ, Sanquan Coll, Sch Med Engn, Xinxiang 453513, Peoples R China
6.Southern Univ Sci & Technol, Dept Comp Sci & Engn, Shenzhen 518055, Peoples R China
7.Univ Punjab, Ctr Appl Mol Biol, Lahore 54000, Pakistan

Ismail, Mehreen,Bai, Baogang,Guo, Jinlei,et al. Experimental Validation of MHC Class I and II Peptide-Based Potential Vaccine Candidates for Human Papilloma Virus Using Sprague-Dawly Models[J]. MOLECULES,2023,28(4).

Ismail, Mehreen.,Bai, Baogang.,Guo, Jinlei.,Bai, Yuhui.,Sajid, Zureesha.,...&Shaikh, Rehan Sadiq.(2023).Experimental Validation of MHC Class I and II Peptide-Based Potential Vaccine Candidates for Human Papilloma Virus Using Sprague-Dawly Models.MOLECULES,28(4).

Ismail, Mehreen,et al."Experimental Validation of MHC Class I and II Peptide-Based Potential Vaccine Candidates for Human Papilloma Virus Using Sprague-Dawly Models".MOLECULES 28.4(2023).